



TECHNOLOGY OFFER

UP-070: A new peptide for therapy of cardiac and/or skeletal muscle dysfunction

Key Facts

- A short new peptide derived from a S100 protein
- Positive inotropic effect on skeletal and cardiac muscle

The Technology

A short peptide derived from an S100 protein with a positive inotropic effect which can be used for treating acute and chronic skeletal muscle or cardiac muscle dysfunctions.

Background

At present, there are no clinical inotropic therapies available for skeletal muscle disorders. Approved therapeutics currently available for the inotropic treatment of cardiomyopathies, such as glycoside derivatives, catecholamines, and phosphodiesterase inhibitors, are afflicted with severe side effects such as increased heart rate and life threatening proarrhythmogenic potential. Therefore, there is an urgent need for novel therapeutics for the inotropic treatment of cardio-myopathies and also therapeutics having the ability to increase the contractile performance of skeletal muscle cells.

Advantages

- short Peptide
- contractility enhancing
- no proarrhythmic side effects
- no heart rate changes

Commercial Opportunity

Drug Development,

Inventors

Most, Voelkers, Remppis & Katus (University Clinic Heidelberg, Cardiology)

Intellectual Property

US Patent application number: 61169962

Reference:

Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R568-77. Epub 2007 Apr 25. Review.

Contact:

Dr. Jörg Rauch
TechnologyTransfer
Faculty of Medicine and Heidelberg University
Medical School
Im Neuenheimer Feld 672
69120 Heidelberg
Tel. +49-(0)6221-56-6426
Fax: +49-(0)6221-56-5714
Email: gerd-joerg.rauch@med.uni-heidelberg.de

In cooperation with

